Dr. Hnik joins iCo Therapeutics as CMO

Vancouver, British Columbia-Peter Hnik, MD, MHS, has been named chief medical officer of iCo Therapeutics Inc. The biotechnology company is developing pre-existing drugs for a range of new conditions affecting isolated biologic environments-areas such as the eye, spinal cord, and joints, where locally administered application of these therapies would have minimal systemic distribution and fewer safety issues.

Vancouver, British Columbia-Peter Hnik, MD, MHS, has been named chief medical officer of iCo Therapeutics Inc. The biotechnology company is developing pre-existing drugs for a range of new conditions affecting isolated biologic environments-areas such as the eye, spinal cord, and joints, where locally administered application of these therapies would have minimal systemic distribution and fewer safety issues.

Dr. Hnik is an ophthalmologist who specializes in glaucoma, neuro-ophthalmology, and retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. Previously, he was associate director of clinical research at QLT, where he played a crucial role in designing and directing clinical trials and related activities for verteporfin PDT (Visudyne, Novartis/QLT). Also, he formerly practiced at the eye clinics of Charles University of Prague and the University of British Columbia, Vancouver.